Chronic administration of nevirapine during pregnancy: Impact of pregnancy on pharmacokinetics

HIV Medicine

Volumn 9, Issue 4, 2008, Pages 214-220

  Capparelli, E V ^a,o   Aweeka, F ^b   Hitti, J ^c   Stek, A ^d   Hu, C ^e   Burchett, S K ^f   Best, B ^a   Smith, E ^g   Read, J S ^h   Watts, H ^h   Nachman, S ⁱ   Thorpe Jr , E M ^j   Spector, S A ^a   Jimenez, E ^k   Shearer, W T ^l   Foca, M ^m   Mirochnick, M ⁿ  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f BOSTON CHILDREN S HOSPITAL   (United States)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^h EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

ⁱ STONY BROOK UNIVERSITY   (United States)

^j UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^k San Juan City Hospital   (Puerto Rico)

^l TEXAS CHILDREN S HOSPITAL   (United States)

^m Boston University ^*  (United States)

ⁿ BOSTON UNIVERSITY   (United States)

^o UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

HIV; Nevirapine; Non nucleoside reverse transcriptase; Pharmacokinetics; Pregnancy

Indexed keywords

ABACAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELIVERY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATERNAL BLOOD; OPEN STUDY; PREGNANCY; PRENATAL PERIOD; PRIORITY JOURNAL; PUERPERIUM; SECOND TRIMESTER PREGNANCY; STUDENT T TEST; THIRD TRIMESTER PREGNANCY; UMBILICAL CORD BLOOD;

ADULT; FEMALE; FETAL BLOOD; HIV INFECTIONS; HIV-1; HUMANS; NEVIRAPINE; POSTPARTUM PERIOD; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY TRIMESTER, SECOND; PREGNANCY TRIMESTER, THIRD; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 41549167294     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2008.00553.x     Document Type: Article

References (24)

1. Mofenson LM, Lambert JS, Stiehm ER et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. N Engl J Med 1999; 341: 385-393.
2. Saitoh A, Hull AD, Franklin P, Spector SA. Myelomeningocele in an infant with intrauterine exposure to efavirenz. J Perinatol 2005; 25: 555-556.
3. Lyons F, Hopkins S, Kelleher B et al. Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy. HIV Med 2006; 7: 255-260.
4. Hitti J, Frenkel LM, Stek AM et al. Maternal toxicity with continuous nevirapine in pregnancy: Results from PACTG 1022. J Acquir Immune Defic Syndr 2004; 36: 772-776.
5. Acosta EP, Zorrilla C, Van Dyke R et al. Pharmacokinetics of saquinavir -SGC in HIV-infected pregnant women. HIV Clin Trials 2001; 2: 460-465.
6. Stek AM, Mirochnick M, Capparelli E et al. Reduced lopinavir exposure during pregnancy. AIDS 2006; 20: 1931-1939.
7. Vidal C, Arnedo M, Garcia F et al. Genotypic and phenotypic resistance patterns in early-stage HIV-1-infected patients failing initial therapy with stavudine, didanosine and nevirapine. Antivir Ther 2002; 4: 283-287.
8. Erickson DA, Mather G, Trager WF, Levy RH, Keirns JJ. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos 1999; 27: 1488-1495.
9. Riska P, Lamson M, MacGregor T et al. Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab Dispos 1999; 27: 895-901.
10. Veldkamp AI, Weverling GJ, Lange JM et al. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS 2001; 15: 1089-1095.
11. Gonzalez de Requena D, Bonora S, Garazzino S et al. Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical setting. Antimicrob Agents Chemother 2005; 49: 3966-3969.
12. Mirochnick M, Fenton T, Gagnier P et al. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis 1998; 178: 368-374.
13. Musoke P, Guay LA, Bagenda D et al. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS 1999; 13: 479-486.
14. Haberi A, Hentig N, Carlebach A, Kurowski M, Harder S, Staszewski S. Nevirapine plasma exposure is decreased in pregnant women. Proceedings of the XV International AIDS Conference. Bangkok, July 2004 [Abstract TuPeB4644].
15. Food and Drug Administration. Draft Guidance for Pharmacokinetic Studies During Pregnancy -October 2004. http://www.fda.gov/cder/guidance/ 5917dft.htm 2004.
16. Fletcher CV, Jiang H, Brundage RC et al. Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359. J Infect Dis 2004; 189: 1176-1184.
17. Kappelhoff BS, van Leth F, MacGregor TR, Lange J, Beijnen JH, Huitema AD. Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. Antivir Ther 2005; 10: 145-155.
18. Tracy TS, Venkataramanan R, Glover DD, Caritis SN. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A activity) during pregnancy. Am J Obstet Gynecol 2005; 192: 633-639.
19. de Maat MM, Huitema AD, Mulder JW, Meenhorst PL, van Gorp EC, Beijnen JH. Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals. Br J Clin Pharmacol 2002; 54: 378-385.
20. Stern JO, Robinson PA, Love J, Lanes S, Imperiale MS, Mayers DL. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV-infected patients. J Acquir Immune Defic Syndr 2003; 34 (Suppl. 1): 21-33.
21. Public Health Service Task Force. Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States, November 2 2007. http://aidsinfo.nih.gov/contentfiles/PerinatalGL.pdf 2007.
22. Camus M, Delomenie C, Didier N et al. Increased expression of MDR1 mRNAs and P-glycoprotein in placentas from HIV-1-infected women. Placenta 2006; 27: 699-706.
23. Marzolini C, Rudin C, Decosterd LA et al. Transplacental passage of protease inhibitors at delivery. AIDS 2002; 16: 889-893.
24. Gingelmaier A, Kurowski M, Kästner R et al. Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery. AIDS 2006; 20: 1737-1743.